Upgrade to SI Premium - Free Trial

Phreesia Announces Second Quarter Fiscal 2027 Results

September 2, 2026 4:03 PM

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)-- Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026.

“Phreesia delivered a solid fiscal second quarter, with revenue growth and profitability expansion in line with our expectations. We generated positive operating and free cash flow again this quarter, which together with available cash allowed us to reduce debt principal by over $23 million while maintaining a healthy cash balance,” said CEO and Co-Founder Chaim Indig. “We remain enthusiastic about two products that we believe will drive future growth, AccessOne and ProviderConnect, as well as the impact that our artificial intelligence (AI) investments are beginning to have on many aspects of our products and broader organization.”

Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal 2027 Stakeholder Letter.

Fiscal Second Quarter Ended July 31, 2026 Highlights

Recent Developments

Restructuring Plan

On May 7, 2026, we implemented a restructuring plan (the “Plan”) intended to reduce operating expenses and better align the cost structure with our current business priorities. The Plan includes the elimination of approximately 220 positions, approximately half of which are contractor roles. We expect total restructuring charges in connection with the Plan to be approximately $10 million, substantially all of which are expected to consist of employee transition costs, severance payments and related employee benefits, and taxes. Restructuring charges of approximately $2.8 million were recognized for the Plan during the second quarter of fiscal 2027. We expect the Plan to be substantially completed during fiscal year 2027.

Fiscal 2027 Outlook

We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted over the past several quarters, there is now more variability in our network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in our March 2026 earnings disclosure. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne (as defined below) and no additional revenue from potential future acquisitions completed between now and January 31, 2027.

We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. As a reminder, in May 2026, we implemented a restructuring plan intended to reduce operating expenses and better align our cost structure with our current business priorities. The plan is expected to result in meaningful annualized run-rate expense savings, which were reflected in our Adjusted EBITDA outlook provided on March 30, 2026 and reaffirmed on May 27, 2026.

We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are maintaining our outlook for total revenue per AHSC to grow in the low-single-digit percentage range in fiscal 2027.

We believe our cash, cash equivalents, restricted cash and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations for at least the next twelve months. As of July 31, 2026 we had $61 million in borrowings outstanding under our credit facility with Capital One.

Non-GAAP3 Financial Measures

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit), which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP Financial Measures” below.

Available Information

We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding our restructuring plan, including the anticipated amount, timing and composition of restructuring charges, reductions in operating expenses and resulting expense savings; the expected results of the acquisition of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne” and such acquisition, the “AccessOne Acquisition”) discussed herein, including anticipated additional revenue; our ability to meet our obligations for the next twelve months and achieve our fiscal 2027 outlook with our current cash, cash equivalents, restricted cash and cash generated in our normal operations; our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC; our ability to continue generating positive net income and free cash flow; our business strategy and operating plans; the factors that drive our revenue growth; our growth expectations and strategies for the AccessOne business and ProviderConnect; our ability to offer the AccessOne solution to additional clients and access to capital; our expectations regarding new solutions and solutions under development and the use of artificial intelligence in our solutions; and our expectations regarding the impacts of AI across our products and broader organization. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in our credit facility with Capital One and the securitization program with PNC Bank; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

Conference Call Information

We will hold a conference call on Wednesday, September 2, 2026 at 5:00 p.m. Eastern Time to review our fiscal 2027 second quarter financial results. To participate in our live conference call and webcast, please dial (833) 461-5787 (or (626) 884-3620 for international participants) using conference code number 285419602 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Phreesia

Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Phreesia, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

July 31, 2026

January 31, 2026

(Unaudited)

Assets

Current:

Cash, cash equivalents and restricted cash (including restricted cash of $— and $1,691 as of July 31, 2026 and January 31, 2026, respectively)

$

72,945

$

73,830

Settlement assets

26,746

32,999

Accounts receivable, net of allowance for doubtful accounts of $879 and $1,523 as of July 31, 2026 and January 31, 2026, respectively

89,406

97,453

Cardholder receivables

29,351

38,330

Deferred purchase price receivables

14,799

18,003

Accrued interest and fees receivables

723

840

Deferred contract acquisition costs

394

410

Prepaid expenses and other current assets

19,139

17,978

Total current assets

253,503

279,843

Property and equipment, net of accumulated depreciation and amortization of $90,281 and $94,193 as of July 31, 2026 and January 31, 2026, respectively

18,122

20,332

Capitalized internal-use software, net of accumulated amortization of $77,389 and $69,390 as of July 31, 2026 and January 31, 2026, respectively

54,127

54,270

Operating lease right-of-use assets

1,205

2,002

Deferred contract acquisition costs

130

338

Intangible assets, net of accumulated amortization of $18,728 and $13,489 as of July 31, 2026 and January 31, 2026, respectively

74,522

79,761

Goodwill

171,468

170,064

Deferred tax assets

990

1,593

Other assets (includes $1,691 and $— of long-term restricted cash as of July 31, 2026 and January 31, 2026, respectively)

6,669

2,442

Long-term cardholder receivables

59,587

47,723

Long-term deferred purchase price receivables

6,654

5,422

Total Assets

$

646,977

$

663,790

Liabilities and Stockholders’ Equity

Current:

Settlement obligations

$

26,746

$

32,999

Current portion of debt and finance lease liabilities

5,281

7,971

Current portion of operating lease liabilities

824

1,254

Accounts payable

12,237

11,477

Accrued expenses

35,706

41,257

Due to healthcare providers

29,737

38,056

Deferred revenue

32,573

49,522

Other current liabilities

731

705

Total current liabilities

143,835

183,241

Long-term debt and finance lease liabilities

61,165

92,117

Operating lease liabilities, non-current

677

1,107

Long-term due to healthcare providers

59,734

45,329

Long-term deferred revenue

4,687

244

Long-term deferred tax liabilities

4,589

4,498

Other long-term liabilities

439

47

Total Liabilities

275,126

326,583

Commitments and contingencies

Stockholders’ Equity:

Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; no shares issued or outstanding as of both July 31, 2026 and January 31, 2026

Common stock, $0.01 par value—500,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; 63,516,793 and 62,020,186 shares issued as of July 31, 2026 and January 31, 2026, respectively

635

620

Additional paid-in capital

1,212,775

1,181,679

Accumulated deficit

(794,309

)

(799,190

)

Accumulated other comprehensive loss

(621

)

(382

)

Treasury stock, at cost, 1,476,215 and 1,355,169 shares as of July 31, 2026 and January 31, 2026, respectively

(46,629

)

(45,520

)

Total Stockholders’ Equity

371,851

337,207

Total Liabilities and Stockholders’ Equity

$

646,977

$

663,790

Phreesia, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

Three months ended
July 31,

Six months ended
July 31,

2026

2025

2026

2025

Revenue:

Subscription and related services

$

52,695

$

53,702

$

105,416

$

108,057

Payment solutions(1)

38,489

28,392

80,430

58,317

Network solutions

38,274

35,161

74,547

66,817

Total revenues

129,458

117,255

260,393

233,191

Expenses:

Cost of revenue (excluding depreciation and amortization)

19,271

17,398

36,930

34,035

Payment solutions expense(1)

23,914

20,243

49,589

41,671

Sales and marketing

24,587

25,396

48,796

51,439

Research and development

27,571

29,274

55,899

61,103

General and administrative

16,512

19,042

34,873

35,450

Depreciation

3,340

3,279

6,711

6,265

Amortization

6,655

4,130

13,238

8,022

Total expenses

121,850

118,762

246,036

237,985

Operating income (loss)

7,608

(1,507

)

14,357

(4,794

)

Other (expense) income, net

(2,888

)

336

(2,895

)

674

Loss on extinguishment of debt

(17

)

Interest expense

(1,729

)

(391

)

(4,028

)

(826

)

Interest income

248

999

545

1,204

Total other (expense) income, net

(4,369

)

944

(6,395

)

1,052

Income (loss) before income tax expense

3,239

(563

)

7,962

(3,742

)

Income tax (expense) benefit

(1,321

)

1,217

(3,081

)

482

Net income (loss)

$

1,918

$

654

$

4,881

$

(3,260

)

Net income (loss) per share attributable to common stockholders:

Basic

$

0.03

$

0.01

$

0.08

$

(0.06

)

Diluted

$

0.03

$

0.01

$

0.08

$

(0.06

)

Weighted-average common shares outstanding:

Basic

61,878,316

59,591,545

61,419,374

59,261,722

Diluted

62,463,449

61,685,811

62,259,892

59,261,722

(1) Beginning with the fourth quarter of the fiscal year ended January 31, 2026, the revenue line previously labeled “Payment processing fees” was relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” was relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

Phreesia, Inc.

Unaudited Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

Three months ended
July 31,

Six months ended
July 31,

2026

2025

2026

2025

Net income (loss)

$

1,918

$

654

$

4,881

$

(3,260

)

Other comprehensive (loss) income:

Net change in unrealized (loss) gain on cash flow hedges

(37

)

(199

)

(118

)

208

Change in foreign currency translation adjustments

(13

)

(73

)

(121

)

(45

)

Other comprehensive (loss) income

(50

)

(272

)

(239

)

163

Comprehensive income (loss)

$

1,868

$

382

$

4,642

$

(3,097

)

Phreesia, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

Three months ended
July 31,

Six months ended
July 31,

2026

2025

2026

2025

Operating activities:

Net income (loss)

$

1,918

$

654

$

4,881

$

(3,260

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization

9,995

7,409

19,949

14,287

Stock-based compensation expense

11,875

16,230

25,429

33,455

Amortization of deferred financing costs

132

62

566

124

Loss on extinguishment of debt

17

Cost of Phreesia hardware purchased by customers

245

157

433

593

Deferred contract acquisition costs amortization

108

242

224

352

Non-cash operating lease expense

564

218

797

433

Deferred taxes

1,136

(1,583

)

1,813

(1,498

)

Gains and losses for fair value option

2,812

2,812

Changes in operating assets and liabilities:

Accounts receivable

185

(1,820

)

7,916

(3,310

)

Cash received for sale of receivables

995

8,706

Accrued interest receivable

(12

)

117

Prepaid expenses and other assets

(2,640

)

(2,660

)

(1,812

)

(2,916

)

Deferred contract acquisition costs

(351

)

(351

)

Accounts payable

489

2,068

648

329

Accrued expenses and other liabilities

4,982

(1,289

)

(2,003

)

(2,180

)

Payment of due to provider for receivables sold to securitization

(8,480

)

(13,540

)

Lease liabilities

(452

)

(238

)

(862

)

(490

)

Deferred revenue

(5,524

)

(4,264

)

(13,841

)

(5,883

)

Net cash provided by operating activities

18,328

14,835

42,250

29,685

Investing activities:

Collections of cardholder receivables held for investment and deferred purchase price

26,672

39,024

Capitalized internal-use software

(4,012

)

(3,435

)

(7,252

)

(7,323

)

Purchases of property and equipment

(492

)

(1,767

)

(4,802

)

(5,271

)

Net cash provided by (used in) investing activities

22,168

(5,202

)

26,970

(12,594

)

Financing activities:

Proceeds from issuance of common stock upon exercise of stock options

10

114

141

242

Treasury stock to satisfy tax withholdings on stock compensation awards

(14

)

(1,109

)

Proceeds from employee stock purchase plan

236

575

758

1,343

Finance lease payments

(1,188

)

(2,510

)

(2,868

)

(3,886

)

Principal payments on financing agreements

(364

)

(328

)

(719

)

(648

)

Debt issuance costs and loan facility fee payments

(2,259

)

(38

)

Debt extinguishment costs

(42

)

Proceeds from debt instruments

92,240

Principal payments on debt instruments

(23,500

)

(121,500

)

Payments due to provider for unfunded receivables

(17,462

)

(33,017

)

Net cash used in financing activities

(42,282

)

(2,149

)

(68,375

)

(2,987

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

25

(89

)

(39

)

(58

)

Net (decrease) increase in cash, cash equivalents and restricted cash

(1,761

)

7,395

806

14,046

Cash, cash equivalents and restricted cash – beginning of period

76,397

90,871

73,830

84,220

Cash, cash equivalents and restricted cash – end of period

$

74,636

$

98,266

$

74,636

$

98,266

Supplemental information of non-cash investing and financing information:

Non-cash activity related to credit card receivables and deferred purchase price

$

20,992

$

$

48,709

$

Exchange of right of use asset for property and equipment

$

$

$

57

$

Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities

$

2,140

$

2,461

$

2,140

$

2,461

Capitalized stock-based compensation

$

238

$

320

$

580

$

652

Issuance of stock to settle liabilities for stock-based compensation

$

919

$

1,346

$

8,972

$

7,854

Cash paid for:

Interest

$

703

$

330

$

4,551

$

654

Income taxes

$

2,884

$

763

$

4,065

$

1,314

Reconciliation of cash, cash equivalents and restricted cash shown in statements of cash flows

Cash, cash equivalents and restricted cash per balance sheets

$

72,945

$

98,266

$

72,945

$

98,266

Restricted cash included in other long-term assets

1,691

1,691

Total cash, cash equivalents and restricted cash shown in statements of cash flows

$

74,636

$

98,266

$

74,636

$

98,266

Non-GAAP Financial Measures

This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three and nine months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted.

We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit) which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss), and our GAAP financial results.

The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Adjusted EBITDA

Three months ended
July 31,

Six months ended
July 31,

(in thousands, unaudited)

2026

2025

2026

2025

Net income (loss)

$

1,918

$

654

$

4,881

$

(3,260

)

Interest expense

1,729

391

4,028

826

Interest income

(248

)

(999

)

(545

)

(1,204

)

Income tax expense (benefit)

1,321

(1,217

)

3,081

(482

)

Depreciation and amortization

9,995

7,409

19,949

14,287

Stock-based compensation expense

11,875

16,230

25,429

33,455

Loss on extinguishment of debt

17

Other expense (income), net

2,888

(336

)

2,895

(674

)

Other items affecting comparability(1)

3,442

3,659

Adjusted EBITDA

$

32,920

$

22,132

$

63,394

$

42,948

(1) For the three months ended July 31, 2026, other items affecting comparability consisted of $0.7 million of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition and $2.8 million of severance, taxes and employee benefit costs associated with the restructuring plan. For the six months ended July 31, 2026, other items affecting comparability consisted of $0.9 million of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition and $2.8 million of severance, taxes and employee benefit costs associated with the restructuring plan.

We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

Additionally, free cash flow is a supplemental measure of our liquidity that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position.

The following table presents a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Free cash flow

Three months ended
July 31,

Six months ended
July 31,

(in thousands, unaudited)

2026

2025

2026

2025

Net cash provided by operating activities

$

18,328

$

14,835

$

42,250

$

29,685

Less:

Capitalized internal-use software development costs

(4,012

)

(3,435

)

(7,252

)

(7,323

)

Purchases of property and equipment

(492

)

(1,767

)

(4,802

)

(5,271

)

Free cash flow

$

13,824

$

9,633

$

30,196

$

17,091

Phreesia, Inc.

Supplementary Information

(Unaudited)

Three months ended
July 31,

Six months ended
July 31,

(in thousands)

2026

2025

2026

2025

GAAP operating expenses

General and administrative

$

16,512

$

19,042

$

34,873

$

35,450

Sales and marketing

24,587

25,396

48,796

51,439

Research and development

27,571

29,274

55,899

61,103

Cost of revenue (excluding depreciation and amortization)

19,271

17,398

36,930

34,035

$

87,941

$

91,110

$

176,498

$

182,027

Stock compensation included in GAAP operating expenses

General and administrative

$

5,392

$

6,362

$

10,881

$

12,935

Sales and marketing

3,792

4,745

7,694

9,919

Research and development

2,205

4,204

5,770

8,597

Cost of revenue (excluding depreciation and amortization)

486

919

1,084

2,004

$

11,875

$

16,230

$

25,429

$

33,455

Other items affecting comparability included in GAAP operating expenses

General and administrative

$

848

$

$

1,065

$

Sales and marketing

300

300

Research and development

2,022

2,022

Cost of revenue (excluding depreciation and amortization)

272

272

Phreesia, Inc.

Key Metrics

(Unaudited)

Three months ended
July 31,

Six months ended
July 31,

2026

2025

2026

2025

Average number of healthcare services clients ("AHSCs")

4,744

4,467

4,726

4,439

Total revenue per AHSC

$

27,289

$

26,249

$

55,098

$

52,532

The definitions of our key metrics are presented below.

Phreesia, Inc.

Additional Information

(Unaudited)

Three months ended

Six months ended

July 31, 2026

January 31, 2026(1)

July 31, 2026

January 31, 2026(1)

Total managed payments (in billions)

$

1.626

$

1.560

$

3.412

$

3.194

Payment solutions revenue rate

2.4

%

2.3

%

2.4

%

2.0

%

(1) The AccessOne Acquisition was completed on November 12, 2025. Reflects inclusion of the business operations of AccessOne from November 12, 2025 to January 31, 2026 and therefore the payment solutions revenue rate for the three and six months ended January 31, 2026 is not indicative of AccessOne’s full performance for the periods presented.

Total managed payments and payment solutions revenue rate were introduced in the first quarter of fiscal 2027. We believe these metrics will enable investors to better evaluate the performance of our payment solutions business following the AccessOne Acquisition during the fourth quarter of fiscal 2026, which introduced new revenue-generating activities. These metrics have replaced patient payment volume and payment facilitator volume percentage, which reflected only the legacy Phreesia payment processing business4. Total managed payments reflects both the transactional activity we facilitate and the financing solutions we provide to healthcare organizations and patients. These metrics provide a clear and consistent framework for understanding how payment activity translates into revenue, enabling investors to more effectively assess the growth, performance and overall value of our payment solutions business.

_____________________________

1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of Fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See “Non-GAAP Financial Measures” for a reconciliation of free cash flow to the closest GAAP measure.

3 GAAP is defined as generally accepted accounting principles in the United States.

4 For periods prior to the three months ended April 30, 2026, we presented (i) patient payment volume (measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors) and (ii) payment facilitator volume percentage (defined as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume).

Investor Relations Contact:



Balaji Gandhi

Phreesia, Inc.



[email protected]

(929) 506-4950



Media Contact:



Nicole Gist

Phreesia, Inc.



[email protected]

(407) 760-6274

Source: Phreesia, Inc.

Categories

Business Wire Press Releases